Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Logo
ASMB US​

Assembly Biosciences, Inc.(ASMB US)

$19.84-0.442.17%Ext:$19.04-0.804.05%(Market Closed · 23:47:22 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Assembly Biosciences, Inc. — Company Profile

Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UQ
CEO
Jason A. Okazaki
Headquarters
South San Francisco, CA, US
IPO Date
Dec 17, 2010
Employees
73
Website
www.assemblybio.com

Key Metrics

Price
$22.54
Market Cap
$446.68M
Revenue (TTM)
$8.21M
Net Income (TTM)
$-9079000.00
EPS (TTM)
-0.54
P/E (TTM)
-69.98
P/B (TTM)
2.25
Dividend Yield
0.00%
ROE (TTM)
-4.57%
ROA (TTM)
-3.86%
Operating Margin
-138.44%
Beta
1.21

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.

Website
www.assemblybio.com
Location
South San Francisco, CA, US
Phone833 509 4583
Employees73
CEOJason A. Okazaki
Sector
Health Care
Industry
Pharmaceuticals
IPO DateDec 17, 2010

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(882)

Expand
  • S-8Registration statement (employee benefit plan)20 Aug
  • SC 13G/AASSEMBLY BIOSCIENCES, INC.14 Aug
  • 8-K/AResults of Operations and Financial Condition14 Aug
  • 10-QQ2ended 30 Jun 202613 Aug
  • 8-KCompletion of Acquisition or Disposition of Assets13 Aug
  • SC 13G/AASSEMBLY BIOSCIENCES, INC.13 Aug
  • SC 13G/AASSEMBLY BIOSCIENCES, INC.4 Aug
  • 4Statement of changes in beneficial ownership18 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers5 Jun

News

  • Analyzing RYTHM (NASDAQ:RYM) and Assembly Biosciences (NASDAQ:ASMB)6 Oct
  • Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 20265 Oct
  • Best Momentum Stocks to Buy for September 17th17 Sep
  • New Strong Buy Stocks for September 17th17 Sep
  • Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference10 Sep
  • Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks9 Sep
  • Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program8 Sep
  • Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?7 Sep
  • Should You Buy Assembly Biosciences (ASMB) After Golden Cross?4 Sep
  • 5 Stocks With Recent Price Strength Buoyed by a Strong August4 Sep
  • Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep going3 Sep
  • Best Momentum Stocks to Buy for August 25th25 Aug
  • New Strong Buy Stocks for August 25th25 Aug
  • Best Momentum Stocks to Buy for August 21st21 Aug
  • New Strong Buy Stocks for August 21st21 Aug
  • Are You Looking for a Top Momentum Pick? Why Assembly Biosciences (ASMB) is a Great Choice20 Aug
  • Wall Street Analysts Think Assembly Biosciences (ASMB) Could Surge 40.66%: Read This Before Placing a Bet20 Aug
  • Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal16 Aug
  • Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates13 Aug
  • Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates13 Aug

Mentions in Filings

  • … Dermatology Portfolio Leader. Dr. Johnson-Pratt served on the board of TRACON Pharmaceuticals, then a publicly-held company, from March 2021 to September 2024. Dr. Johnson-Pratt currently serves on the board of <strong>Assembly Biosciences, Inc.</strong>, a biopharmaceutical company where she was first elected to the board in May 2021. Dr. Johnson-Pratt received her B.S. and M.D. from Howard University, with further post-doctoral training in Internal Medicine, C …
    Aspen Neuroscience, Inc.Assembly Biosciences, Inc.·S-1/A - Registration statement (general form, amendment)·Q4 26·22 Oct
  • … gement. Prior to joining Lilly, Dr. Mahony served in sales and marketing roles in Europe for over a decade for Schering-Plough, Amgen, and Bristol-Myers Squibb. Dr. Mahony has served on the board of directors of <strong>Assembly Biosciences, Inc.</strong> since December 2017, on the board of directors of Axsome Therapeutics, Inc. since October 2023, and on the board of directors of Catalent, Inc. since February 2025. She previously served on the board of director …
    Zymeworks Inc.Assembly Biosciences, Inc.·PRE 14A - Preliminary proxy statement·Q4 26·16 Oct
  • … Dermatology Portfolio Leader. Dr. Johnson-Pratt served on the board of TRACON Pharmaceuticals, then a publicly-held company, from March 2021 to September 2024. Dr. Johnson-Pratt currently serves on the board of <strong>Assembly Biosciences, Inc.</strong>, a biopharmaceutical company where she was first elected to the board in May 2021. Dr. Johnson-Pratt received her B.S. and M.D. from Howard University, with further post-doctoral training in Internal Medicine, C …
    Aspen Neuroscience, Inc.Assembly Biosciences, Inc.·S-1 - Registration statement (general form)·Q4 26·9 Oct
  • … Therapeutics 2017 Partnership was later unwound and the microbiome candidates returned; Assembly ultimately exited microbiome work. Note: public deal descriptions emphasize UC and Crohn’s, not CDI. ( Fierce Biotech ) Preclinical $50M upfront plus milestones and royalties (per deal announcement coverage). ( BioSpace ) Microbiome GI programs (often cited as ABI - M201, ABI - M301; not CDI specific) Allergan (later AbbVie) <strong>Assembly Biosciences</strong> 2017
    Immuron LtdAssembly Biosciences, Inc.·EX-99.1 - 6-K - PRESENTATION TO COFFEE MICROCAPS CONFERENCE·Q1 27·21 Sep
  • … Scrip, Inc. (“BioScrip”) (Nasdaq: BIOS). BioScrip is a leading national provider of infusion and home care management solutions. Since July 2010, Mr. Holubiak has served as a member of the board of directors of <strong>Assembly Biosciences, Inc.</strong> (“Assembly”) (Nasdaq: ASMB) and its predecessor Ventrus Biosciences, Inc. Assembly is a biopharmaceutical company developing innovative, small molecule therapeutics for hepatitis B virus (HBV), hepatitis delta …
    CITIUS ONCOLOGY, INC.Assembly Biosciences, Inc.·ARS - Annual report to security holders·FY25·26 Aug
  • … oScrip, Inc. (“BioScrip”) (Nasdaq: BIOS). BioScrip is a leading national provider of infusion and home care management solutions. Since July 2010, Mr. Holubiak has served as a member of the board of directors of <strong>Assembly Biosciences, Inc.</strong> (“Assembly”) (Nasdaq: ASMB) and its predecessor Ventrus Biosciences, Inc. Assembly is a biopharmaceutical company developing innovative, small molecule therapeutics for hepatitis B virus (HBV), hepatitis delta v …
    CITIUS ONCOLOGY, INC.Assembly Biosciences, Inc.·DEF 14A - DEFINITIVE PROXY STATEMENT·Q4 26·26 Aug

Key Stats

Trading

Px/Chg 1D$22.54 / -1.91%
Prev Close$36.60
% of 52Wk H88.84%
Avg Volume157.09K
Beta1.21
Mkt Cap446.68M
FD Mkt Cap699.15M

Float

Shrs Out/Float19.82M / 12.47M
Short Float0.27%
Days to Cover6.59
Stock Repurchased$0.00

Current Valuation

EV418.05M
EV/EBITDA-58.42
EV/Sales5.88
P/B2.25
P/S6.28
FCF Yield-4.95%
ROE-4.57%
ROA-3.86%
Current Ratio6.65

Estimates

P/E-69.98
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-7.34-0.52-0.94-1.8515.92-49.29
Price / Sales14.690.008.062.618.2854.48
Price / Book Value1.640.591.412.231.702.25
Price / Free Cash Flow1.01-0.572.57-1.4624.74-20.23
ENTERPRISE VALUE METRICS
Enterprise Value158.7-0.540.339.3295.8418.8
Enterprise Value / Sales12.990.005.621.386.9651.00
Enterprise Value / EBITDA-6.880.01-0.63-0.8713.37-46.27
Enterprise Value / EBIT-6.850.01-0.62-0.8613.39-46.13

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue84.4%6.3-7.228.572.3
Gross Income84.3%6.3-69.1-41.728.572.2
EBITDA-49.3%-90.6-92.5-64.2-45.3-6.0
EBIT-49.1%-91.1-93.0-64.6-45.4-6.1
Net Income-53.4%-129.9-93.1-61.2-40.2-6.1
EPS (Diluted)-64.8%-36.00-22.82-13.38-6.69-0.55
BALANCE SHEET
Cash & ST Inv14.1%146.691.6130.2112.1248.1
Total Assets7.8%191.1101.8136.8119.2257.6
Total Liabilities23.1%22.119.195.785.850.8
Total Shareholder Equity5.2%168.982.741.133.4206.8
CASH FLOW
Net Operating Cash Flow-18.6%-93.4-84.522.7-51.1-41.1
Cap Ex-61.8%-3.1-0.1-0.3-0.0-0.1
Free Cash Flow-19.2%-96.5-84.622.5-51.1-41.2

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)19.77
Basic Shares19.82
Market Cap391.8
Diluted Shares16.90
Fully Diluted Shares Outstanding16.90
Fully Diluted Market Cap334.1
+Consolidated Debt2.5
−In-the-Money Convertible Debt—
+Capital Leases0.6
+Operating Leases—
−Cash & Equivalents-31.1
−Short-term Investments-195.5
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value363.2

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US